🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congratulations to Keros and Takeda for landing DealForma's December 2024 Top Biopharma Partnership. Check out the details of this deal hubs.ly/Q03257h50

Here's #biotech 2024 by the numbers. Venture surges, deal flow jumps (but curb your enthusiasm), licensing looks better, IPOs sputtered, PIPEs performed (alt finance) and M&A now has nowhere to go but up -- which it is. My bet is that the megarounds we saw in H2 of 24 is a bet

DealForma’s 2024 review of autoimmune therapeutics saw robust activity across R&D partnerships, M&A, venture funding, and IPOs, highlighting strong momentum and pharma demand for next-gen immunology platforms. Check out our research. hubs.ly/Q03kmz9F0

Data from DealForma shows Chinese companies now account for 42% of $50M+ licensing deals, highlighting China’s growing role in global biopharma innovation. Read more on our blog. hubs.ly/Q03kmFjM0

Venture capital $ for biopharmas/biotechs working on autoimmune diseases increased to $2.6B in '24 —up from $1.6B in '23. M&A was up in '24 too: $10.6B in upfront $ in 11 deals h/t DealForma Chris Dokomajilar 1/n

Data from DealForma highlights the rapid rise of Chinese biotechs, now accounting for 42% of major licensing deals, while Big Pharma continues to prioritize mid-stage assets. Read the article here hubs.ly/Q03l71Lc0

DealForma’s review of gene therapy shows that during 2024 gene therapy attracted a significant share across R&D partnerships, M&A, and venture funding, with a focus on CNS, oncology, ophthalmology, renal, and rare diseases. Read our research hubs.ly/Q03lHqB50

DealForma review of Q1 2025 saw a surge in biopharma venture funding, with several companies securing $200 million+ rounds to advance differentiated therapies across metabolic, neurological, immunological, and ophthalmic diseases. Check out our research hubs.ly/Q03mRJhB0

Biopharma therapeutics and platforms IPO activity showed strong momentum in Q1 2025. Over $3 billion was raised through IPOs, PIPEs, and follow-on offerings, signaling a market rebound. Check out our research hubs.ly/Q03nH3Mb0

CNBC uses data from DealForma to report on Pfizer's and China's 3SBio's deal to license cancer drug. Watch the clip hubs.ly/Q03q0Jpt0

AI drug discovery deals now feature nine‑figure upfronts and billion‑dollar milestones, with DealForma data showing a shift toward biologics, real‑world data, and broader pharma-AI partnerships. Read Nature's article here. hubs.ly/Q03qWfFX0

Our Q1 2025 review shows strong M&A and funding momentum across MedTech, especially in cardio, ortho, diabetes, ophthalmology, and digital health. Check out our research hubs.ly/Q03qWggg0

Stifel’s ASCO 2025 recap, with DealForma data, highlights ADCs, bispecifics, evolving buyer strategies, and China’s rise in oncology licensing. Read it here hubs.ly/Q03r8HQ-0

Cancer activity by TA was strong in Q1 2025, with significant R&D partnerships, acquisitions, and venture investments signaling continued growth. Read our research. hubs.ly/Q03s2lDZ0

Nature’s article on biotech’s shifting landscape cites DealForma data showing 2025 venture financing nearing $27B, with more money going to fewer, well-funded startups. Read it here hubs.ly/Q03sPSc20

Your first look at biopharma-to-biopharma M&A through Q2. Capstan/AbbVie bumped up the median upfront M&A value. DealForma customers get reports full of charts on licensing and funding activity in Q2. Contact me if you are interested

M&A bankers had the busiest year in a while. Here's a look at H1 2025 M&A when we zoom out the database to broader life sciences, medtech, and CDMOs.

Biopharma licensing brought in $10 billion upfront in H1 2025. $7.7 billion of this was from 18 deals that had more than $100M upfront to challenge full-year 2024.

The first half of 2025 saw robust activity in the autoimmune space, with high-value R&D partnerships, strategic M&A deals, and strong venture funding. Check out our research hubs.ly/Q03wyFYh0

The Endpoints article highlights how biotech dealmaking has remained resilient in 2025 despite a tough fundraising climate, with a notable surge in licensing, M&A, and AI-driven agreements keeping activity high. Read it here hubs.ly/Q03wZDhH0